Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis
Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, Alam M, Putri FA, Bastard M, et al. (26 authors)
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020-07
Abstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.
MeSH terms
- Humans
- Mycobacterium tuberculosis
- Tuberculosis, Multidrug-Resistant
- Nitroimidazoles
- Oxazoles
- Antitubercular Agents
- Treatment Outcome